MARCHF5 and acute myeloid leukemia: When genome-wide CRISPR/Cas9 techniques were applied in a resistant to VEN AML mouse model, the levels of MARCH5, UBE2K and UBE2J2 were significantly decreased after exposure to VEN, suggesting a combined lethal effect.